MedKoo product information:

PRT-062607 

PRT062607 is an oral inhibitors of Spleen Tyrosine Kinase (Syk) and Janus Kinase (JAK).  Syk and JAK play key roles in signaling pathways that modulate inflammation and certain cancers.  PRT062607 has been shown to be a highly specific inhibitor of Syk in a broad panel of in vitro kinase and cellular assays.

PRT062607 has been shown to be a highly specific inhibitor of Syk in a broad panel of in vitro kinase and cellular assays. Kinase selectivity may lead to an agent that is safer and better tolerated than other compounds in development. PRT062607 reduced inflammation in a dose-dependent manner in a number of preclinical in vivo models of rheumatoid arthritis. It has also been effective in killing non-Hodgkin’s lymphoma cell lines and chronic lymphocytic leukemia tumor cells. PRT062607 is currently in a Phase 1 program. Results of a Phase 1 single ascending dose study showed PRT062607 was well tolerated with a profile suitable for once-daily dosing. Portola and Biogen Idec are planning to advance PRT062607 into a Phase 2 program in 2012. (source: Portola's website)

Current developer:   Portola Pharmaceuticals, Inc.